You are here


Imigran - a remedy for migraines, is an selective agonist of serotonin 5HT1 receptors.





N02CC01 Sumatriptan

Indications of immigraine

The drug is indicated for rapid pain relief with migraines (with the presence of aura, and without it).

Release form

Produced in tablets, 6 pieces per blister plate (1 blister per package with LS) or 2 pieces per blister (with 3 blister packs in the package).


Sumatriptan is a selective agonist of 5HT receptors (1D), without affecting other 5HT receptors. The end data is located mainly inside the cranial-cerebral vessels.

During the experimental tests, it was found that sumatriptan has a selective vasoconstrictive effect on the vessels located inside the carotid artery system, without acting on the blood circulation in the brain. Through the carotid arteries, the blood reaches intra-, as well as extracranial tissues (for example, to the membranes of the brain), the expansion of the vessels of which leads to the appearance of a migraine.

With the help of experimental tests it was possible to additionally reveal the inhibitory properties of the active component relative to the function of the trigeminal nerve. It is through these two mechanisms that anti-migraine action of sumatriptan appears.

The drug effect begins half an hour after oral administration of drugs (in the amount of 100 mg).


When taken orally, the component is rapidly absorbed, after 45 minutes reaching 70% of the peak level. On average, the maximum plasma index at a dosage of 100 mg is 45 ng / ml. The bioavailability level with internal tablet intake is 14% (in part because of the systemic process of metabolism, and partly due to incomplete absorption).

With plasma protein, the synthesis is weak (14-21%), and the average level of the distribution volume is 17 liters. The average total clearance is about 1160 ml / minute, and in the kidneys the average is about 260 ml / minute.

The clearance outside the kidneys is about 80% of the total, which allows the determination of sumatriptan excretion mainly in the form of decay products. The main one is an indole acetic analogue of the active ingredient. It is excreted in urine (in it it is defined as a free acid, as well as glucuronide conjugated with the substance) and does not have the activity of 5HT1, as well as 5HT2. Other decay products are not identified.

The pharmacokinetic properties of the administered sumatriptan vary slightly during the migraine attack.

Use of immigraine during pregnancy

Prescribe to pregnant women is allowed only taking into account the possible help of the mother in relation to the risk of developing negative symptoms in the fetus.

It is known that when n / to the introduction of the active substance, it penetrates into the mother's milk. Reduce the impact on the child can be if within 12 hours after eating drugs do not breastfeed.


Among the contraindications of drugs:

  • intolerance of the constituent elements of the medicine;
  • a history of myocardial infarction, and in addition spontaneous angina, coronary artery disease, peripheral vascular pathology, or signs that are characteristic of IHD;
  • a history of a temporary circulatory disorder in the brain or a stroke;
  • severe or moderate degree of elevation of blood pressure or a mild form of uncontrolled increase in blood pressure;
  • severe liver failure;
  • taking concomitantly with MAO inhibitors - starting the use of Imigran is allowed at least 2 weeks after stopping the intake of inhibitors;
  • children and adolescence, as there is no information about the safety and effectiveness of drug use in the category of people treated above.

Side effects of immigraine

According to clinical tests such side reactions have been identified:

  • NA bodies: there is often a sense of drowsiness or dizziness, and in addition the sensitivity disorder (including gipoesteziya and paresthesia);
  • authorities CCC: often develops a transient increase in blood pressure (immediately after use tablets), and in addition the tide of blood;
  • respiratory system: often dyspnea;
  • digestive system: often some patients develop vomiting, nausea, although the link to the use of drugs have yet been identified;
  • connective tissues, muscles and skeleton: most of these symptoms are temporary, although they may be intense and affect different parts of the body (including the throat and sternum) - often appear muscle pain or a feeling of heaviness;
  • General disorders: often appear painful sensations, a sense of tension, compression, and the addition of cold or heat (manifestations are usually temporary, although sometimes they are intense and can affect different parts of the body (including those of the throat to the breastbone)). Often there is a strong feeling of weakness or fatigue (these symptoms are temporary and usually also have a moderate or an easy severity);
  • test results: a single small changes occurred in terms of liver function studies.

The results of post-marketing research:

  • immunity: Hypersensitivity (from skin reactions to anaphylaxis development);
  • NA bodies: the appearance of seizures. In some cases, such symptoms arise in people with a tendency to seizures or with a history of states that can lead to such attacks; besides the development of dystonia, tremor, nystagmus, or scotoma;
  • visual organs: the development of diplopia or flicker, deterioration of visual acuity, and in addition the loss of view (it is usually temporary). But these disorders can also occur because of a migraine attack;
  • organs CCC: development tachycardia, angina or bradycardia, increased heart rate, rhythm disorder, transient ischemic ECG changes, spasms of the coronary vessels, lowering blood pressure, myocardial infarction, Raynaud's syndrome;
  • digestive organs: the development of diarrhea or colitis ischemic form;
  • connective tissue, skeleton and musculature: joint pain, cervical sciatica;
  • mental disorders: a sense of excitement;
  • subcutaneous tissue and skin: the development of hyperhidrosis.

Dosing and administration

It is forbidden to drink tablets as a prophylactic against an attack. It is also forbidden to exceed the recommended dosage.

The best time to take the pill - immediately after the onset of an attack, but the medicine will be effective at any stage of it.

Usually, the drug is prescribed in a dose of 50 mg (the size of the first pill). Sometimes it is permitted to increase the dosage to 2 tablets (100 mg).

If there is no effect, you can not take a new dose during the same migraine attack. The next tablet can be taken only after the onset of a new attack.

In the presence of a reaction to the first dosage, but with the subsequent resumption of migraine manifestations, the 2nd tablet is allowed to be used during the next 24 hours, with the minimum interval between doses to be 2 hours. In general, a day (within 24 hours) can take no more than 300 mg of the drug.

Take the pill completely, while washing them with water.


When oral doses of more than 400 mg, only symptoms of adverse reactions occurred. When developing an overdose, it takes at least 10 hours to observe the patient, while carrying out standard support procedures.

There is no information on the effects of peritoneal dialysis or hemodialysis on the parameters of the active component of the drug.

Interactions with other drugs

There is no information on the interaction of the drug with alcoholic beverages, but also with flunarizine, propranolol, and also pizotifenom.

Limited information is available on combined use with drugs that contain ergotamine or other 5-HT1 receptor / tryptone agonists. In theory, a prolonged vasospastic action can develop, as a result of which it is forbidden to combine such drugs. It is not known what the duration should be in the interval between the reception of these drugs - it depends on the type of drugs, as well as their dosages. Since the properties of ergotamine and the agonists of 5-HT1 tryptans / receptors can be enhanced by Imigran, after them a 24-hour interval should be observed before receiving the latter.

In this case, medicines containing ergotamine are forbidden to use for 6 hours after ingestion of Imigran, and agonists of tryptans / receptors 5-HT1 - within 24 hours after using Imigran.

There are single postmarketing mentions that patients developed serotonin intoxication (among manifestations of neuromuscular disorders, changes in the state of the psyche and visceral instability) when the drug is combined with selective inhibitors of reverse serotonin capture. There are also data on the appearance of the aforementioned pathology in the combination of triptans with noradrenaline and inhibitors of reverse serotonin capture.

Storage conditions

The medicine is stored in a place that is closed to children, in standard conditions for medicines. Temperature - no more than 30 ° С.

Shelf life

Imigran allowed to use for 3 years from the date of drug manufacture.

Found an error? Select it and press Ctrl + Enter.

Share on social networks


To simplify the perception of information, this instruction for use of the drug "Imigran" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.